Cumberland Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top 25 shareholders own 58.53% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
40.6%	A. Kazimi	5,700,021	US$6.0m	0.03%	no data
3.76%	Renaissance Technologies LLC	528,163	US$559.9k	-1.86%	no data
2.67%	The Vanguard Group, Inc.	374,251	US$396.7k	0%	no data
2.04%	Bridgeway Capital Management, LLC	286,655	US$303.9k	0%	no data
2.02%	Dimensional Fund Advisors LP	284,005	US$301.0k	-6.61%	no data
1.88%	Kenneth Krogulski	263,598	US$279.4k	2.77%	no data
1.34%	Acadian Asset Management LLC	188,164	US$199.5k	0%	no data
0.78%	BlackRock, Inc.	110,068	US$116.7k	-0.45%	no data
0.54%	BNY Asset Management	75,268	US$79.8k	0%	no data
0.53%	Geode Capital Management, LLC	74,305	US$78.8k	-16.3%	no data
0.42%	Joseph Galante	59,356	US$62.9k	0%	no data
0.27%	James Herman	38,255	US$40.6k	0%	no data
0.27%	James Jones	37,871	US$40.1k	3.91%	no data
0.24%	State Street Global Advisors, Inc.	33,700	US$35.7k	0%	no data
0.21%	Caroline Young	29,017	US$30.8k	2.52%	no data
0.19%	John Hamm	26,003	US$27.6k	0%	no data
0.15%	Cresset Asset Management, LLC	21,275	US$22.6k	1.19%	no data
0.14%	Two Sigma Investments, LP	19,378	US$20.5k	0.25%	no data
0.12%	Todd Anthony	16,328	US$17.3k	0%	no data
0.12%	Northern Trust Global Investments	16,322	US$17.3k	0%	no data
0.071%	Schonfeld Strategic Advisors LLC	10,000	US$10.6k	0%	no data
0.069%	UBS Asset Management AG	9,671	US$10.3k	40.8%	no data
0.044%	Tower Research Capital Europe Limited	6,166	US$6.5k	-6.69%	no data
0.043%	Martin Brown	6,000	US$6.4k	0%	no data
0.033%	Chris Bitterman	4,683	US$5.0k	0%	no data